Genentech announced this week that the FDA has approved an update to its reference rituximab’s (Rituxan) label.
Genentech announced this week that the FDA has approved an update to its reference rituximab’s (Rituxan) label.
In addition to previously being approved for the treatment of non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis (GPA), and microscopic polyangiitis (MPA), the label for reference rituximab will now include information for follow-up treatment in adult patients with GPA and MPA who have achieved disease control with induction treatment.
“As part of our commitment to support people living with rare diseases, we are pleased to provide updated prescribing information for Rituxan to help physicians make more informed decisions about therapeutic options for patients who have achieved disease control with induction treatment,” said Sandra Horning, MD, chief medical officer and head of Global Product Development at Genentech, in a statement.
The label update was based on data from the French Vasculitis Study Group which showed that rituximab plus glucocorticoids resulted in fewer major relapses by month 28 compared with azathioprine treatment. Further, the safety profile was consistent with that previously observed in this patient population. The approval makes the combination treatment the only FDA-approved therapy for these rare blood vessel disorders.
The expanded indications come soon after the FDA’s Oncologic Drug Advisory Committee (ODAC) held a meeting to discuss the Biologics License Application for a proposed rituximab biosimilar, CT-P10, developed by Celltrion and referencing Rituxan.
The committee heard data presented by various speakers that found that, although there were minor differences in clinically active compounds, the totality of the evidence suggested that the proposed biosimilar is highly similar to the reference product.
In a vote on whether the totality of the evidence supported the licensure of CT-P10 as a biosimilar to Rituxan, all 16 committee members voted yes. The product will now be considered for licensure by the FDA, and, if approved, CT-P10 would be the first rituximab biosimilar available in the United States, providing competition to the previously unchallenged Rituxan. Celltrion, notably, is seeking approval for oncology indications only for its biosimilar due to the patent landscape for rituximab.
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Biosimilars Regulatory Roundup for September 2023—Podcast Edition
October 1st 2023On this episode, we discuss several regulatory updates from around the globe, including some European and Japanese approvals, the FDA’s 2-day workshop on the present science behind clinical efficacy testing for biosimilars, and streamlining biosimilar development.
Part 3: Study Questions Usefulness of Clinical Efficacy Trials for Oncology Biosimilars in Europe
November 16th 2023In part 3 of a 3-part series for Global Biosimilars Week, The Center for Biosimilars® reviews an analysis investigating whether clinical efficacy studies have an impact on prescribing decisions for oncology biosimilars across Europe.